drugset / Trial / NCT04801199
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
Phase 3
Completed
355 enrolled
Cadila Pharnmaceuticals
New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM).
Timeline
- Start
- 2020-01-26
- Primary completion
- 2021-01-13
- Completion
- 2021-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPL-2009-0031 | Unknown | 140 mg | Oral |
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |